Descriptive analysis of routine childhood vaccination coverage of selected vaccines in Nigeria (1980-2023) using the Global Burden of Disease Study (2023).
IF 4.2 4区 医学Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY
{"title":"Descriptive analysis of routine childhood vaccination coverage of selected vaccines in Nigeria (1980-2023) using the Global Burden of Disease Study (2023).","authors":"Adewunmi Akingbola, Abiodun Adegbesan, Olajumoke Adewole, Nwaeze Emmanuel, Opeyemi Joshua Alabi, Petra Mariaria","doi":"10.1080/21645515.2026.2684092","DOIUrl":null,"url":null,"abstract":"<p><p>Routine childhood immunization remains an effective public health intervention for reducing childhood morbidity and mortality from vaccine-preventable diseases. This study examined trends in routine childhood vaccination coverage in Nigeria from 1980 to 2023. We conducted a retrospective secondary descriptive analysis using routine childhood vaccination coverage estimates from the Global Burden of Disease Study 2023. Annual national coverage estimates for BCG, DTP3, Polio3, MCV1, and HepB3 vaccines were analyzed from 1980 to 2023. Temporal trends were assessed using line plots and forest plots with associated 95% uncertainty intervals, and the highest and lowest performing years for each vaccine were identified. Coverage for all assessed vaccines was lowest in 1980, followed by gradual expansion during the late 1980s and early 1990s, stagnation between the mid-1990s and early 2000s, and improvement after 2005. Peak coverage occurred between 2019 and 2021 for most vaccines, with BCG reaching the highest in 2021 at 73.6% (95% UI: 64.7-78.3). However, no vaccine achieved the WHO target of 90% national coverage throughout the study period. Although Nigeria has made measurable progress in routine childhood immunization over four decades, coverage remains below optimal levels, highlighting the need for targeted and equitable immunization strategies.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"22 1","pages":"2684092"},"PeriodicalIF":4.2000,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13248905/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Vaccines & Immunotherapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/21645515.2026.2684092","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/8 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Routine childhood immunization remains an effective public health intervention for reducing childhood morbidity and mortality from vaccine-preventable diseases. This study examined trends in routine childhood vaccination coverage in Nigeria from 1980 to 2023. We conducted a retrospective secondary descriptive analysis using routine childhood vaccination coverage estimates from the Global Burden of Disease Study 2023. Annual national coverage estimates for BCG, DTP3, Polio3, MCV1, and HepB3 vaccines were analyzed from 1980 to 2023. Temporal trends were assessed using line plots and forest plots with associated 95% uncertainty intervals, and the highest and lowest performing years for each vaccine were identified. Coverage for all assessed vaccines was lowest in 1980, followed by gradual expansion during the late 1980s and early 1990s, stagnation between the mid-1990s and early 2000s, and improvement after 2005. Peak coverage occurred between 2019 and 2021 for most vaccines, with BCG reaching the highest in 2021 at 73.6% (95% UI: 64.7-78.3). However, no vaccine achieved the WHO target of 90% national coverage throughout the study period. Although Nigeria has made measurable progress in routine childhood immunization over four decades, coverage remains below optimal levels, highlighting the need for targeted and equitable immunization strategies.
期刊介绍:
(formerly Human Vaccines; issn 1554-8619)
Vaccine research and development is extending its reach beyond the prevention of bacterial or viral diseases. There are experimental vaccines for immunotherapeutic purposes and for applications outside of infectious diseases, in diverse fields such as cancer, autoimmunity, allergy, Alzheimer’s and addiction. Many of these vaccines and immunotherapeutics should become available in the next two decades, with consequent benefit for human health. Continued advancement in this field will benefit from a forum that can (A) help to promote interest by keeping investigators updated, and (B) enable an exchange of ideas regarding the latest progress in the many topics pertaining to vaccines and immunotherapeutics.
Human Vaccines & Immunotherapeutics provides such a forum. It is published monthly in a format that is accessible to a wide international audience in the academic, industrial and public sectors.